Zevra Therapeutics Shares Fall After FDA Extends Arimoclomol Review
By Colin Kellaher
Zevra Therapeutics shares fell sharply on Monday after the U.S. Food and Drug Administration extended its review of the rare disease company's lead drug candidate arimoclomol.
Shares of the Celebration, Fla., company were recently down nearly 13% to $6.19.
Zevra, which is seeking approval of arimoclomol for the rare neurodegenerative disorder Niemann-Pick disease type C, said the FDA moved its target action date to Sept. 21 from June 21 after the company provided additional analyses at the agency's request.
Zevra said it remains confident in arimoclomol's potential, and that it will continue to work closely with the FDA as the agency completes its review.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 04, 2024 10:31 ET (15:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks